Bioxydyn targets COPD, lung imaging
Bioxydyn is developing an MRI tool to provide non-invasive regional assessments of lung ventilation/perfusion ratio and measures of changes in pulmonary vascular function.
According to the Manchester, England-based diagnostic imaging company, the technology could improve treatment of lung conditions such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and emphysema and aid cancer specialists and neuroscientists.
Bioxydyn has received commercialization support and advice from UMIP, the University of Manchester's Intellectual Property (UMIP) commercialization company, and funding from The UMIP Premier Fund, which makes late-seed stage investments.
According to the Manchester, England-based diagnostic imaging company, the technology could improve treatment of lung conditions such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and emphysema and aid cancer specialists and neuroscientists.
Bioxydyn has received commercialization support and advice from UMIP, the University of Manchester's Intellectual Property (UMIP) commercialization company, and funding from The UMIP Premier Fund, which makes late-seed stage investments.